Nutritional Composition for Neurodevelopmental Delay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dietary and nutritional interventions have limitations in effectively treating or preventing global developmental delay in children, particularly those with early life brain injuries or at risk of cerebral palsy, as they do not adequately address the concurrent white and grey matter injuries that lead to developmental delays.
Innovation Solution
A composition comprising therapeutically effective amounts of uridine, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), choline, vitamin B12, iodine, and zinc, administered as a supplement to the child's diet, which includes specific ranges of UMP (10-200 mg per 100 kcal), DHA+EPA (250-9000 mg per 100 kcal), choline (60-350 mg per 100 kcal), vitamin B12 (1-5 µg per 100 kcal), iodine (60-150 µg per 100 kcal), and zinc (5-25 mg per 100 kcal, to support neurological development and prevent global developmental delay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dietary and nutritional interventions are used, then basic nutritional needs are met, but they do not adequately address concurrent white and grey matter injuries leading to global developmental delay
Solution Approach 1:
The patent applies the composite materials principle by formulating a nutritional composition that combines multiple specific nutrients (uridine 10-200 mg, DHA 250-9000 mg, EPA 250-9000 mg, choline 60-350 mg, vitamin B12 1-5 µg, iodine 60-150 µg, zinc 5-25 mg) in defined ratios and amounts. This composite nutritional formula addresses both white matter (myelination support via uridine and choline) and grey matter (neuronal development via DHA, EPA, and zinc) injuries simultaneously, thereby improving reliability in treating global developmental delay while managing complexity through standardized formulation
Solution Approach 2:
The patent applies parameter changes by specifying precise quantitative ranges for each nutrient component (e.g., uridine monophosphate at 10-200 mg per 100 kcal, DHA+EPA at 250-9000 mg per 100 kcal). These parameter specifications transform conventional nutritional support into a targeted therapeutic intervention, optimizing the composition to address both white and grey matter injuries effectively
2Reliability
If targeted nutritional supplementation is implemented, then neurodevelopmental outcomes improve, but the intervention requires precise dosing and monitoring
Solution Approach 1:
The patent applies the universality principle by designing a multi-functional nutritional composition that simultaneously supports multiple aspects of brain development: myelination (uridine, choline), neuronal membrane formation (DHA, EPA), neurotransmitter synthesis (vitamin B12, choline), and overall neurodevelopment (zinc, iodine). This single comprehensive formulation addresses multiple pathological processes concurrent in white and grey matter injuries, improving reliability while simplifying administration compared to multiple separate supplements
Data Source
Figure 1~2
Figure 3
AI summary
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic acid (20:5; EPA), or esters thereof, (iii) choline, or salts or esters thereof, in the manufacture of a product for therapeutically treating or preventing global developmental delay or reducing the risk symptoms such as cognitive impairment associated therewith in a child.